- Europe has a thriving biotech sector and with European based CRO, EastHORN joining Novotech our presence give us improved access to this client base.
- Europe is an attractive clinical development region due to the commercial size of the end market, and availability of large patient populations (particularly in central and Eastern Europe).
- Europe has been a leader in the regulation of biosimilars, and so many of these trials occur in Europe.
- Europe is an attractive clinical development region due to the commercial size of the end market, and availability of large patient populations (particularly in central and Eastern Europe) and has been a leader in the regulation of biosimilars, and so many of these trials occur in Europe.
- Europe offers great potential for conducting high-quality clinical research through established centralized healthcare infrastructures, well-educated investigators and an overall high level of interest in the clinical research field in the region. The region offers excellent quality and competitive prices when compared to North America and other regions.
- Novotech expansion to Europe
- As part of our global expansion program, EastHORN, a European CRO joined Novotech in January 2023 which means biotech clients can now access Novotech’s unique and unparalleled suite of early to late phase CRO services across Europe and the US. Novotech will retain its specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Tax Credit for French Clients
EastHORN has accreditation from the French Finance Ministry for French clients to receive research tax credits for expenditure on EastHORN services.
